KeYe Life ’s Investigational Drug KY2 is Accepted by China’s Center for Drug Evaluation (CDE)
2025-04-15
KeYe Life's KY1 Enters Phase I Clinical Trial at Ruijin
2025-03-20
Keye Life's KY2 Oral Small-Molecule Drug Receives FDA Investigational New Drug (IND) Implicit Approval.
2025-02-22
KY1 completes first patient dosing in Phase I clinical trial
2024-10-25
Russian Academy of Engineering Foreign Academician Dr. Zhang Dan was Invited to Visit and Guide Clinical Trials
KeYe Biotech Successfully Holds KY1 Product Clinical Trial Kickoff Meeting
